Triphase Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Triphase Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, g…

2006-06-01 Mysore, Karnataka Active Unlisted Active Compliant
Share
Connect MCP
TP Triphase Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Triphase Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
44/100
Trust Score
Caution Indicated

Triphase Pharmaceuticals Private Limited is assessed as Caution Indicated with a Trust Score of 44/100. Triphase Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2006, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.

Report generated on 15 Aug 2026 from the latest processed filings. Triphase Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Weak
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreCaution Indicated
44/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
43/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
20/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
40/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
35/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 43/100 Caution Indicated
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
  • Litigation present in 2 court forum(s).
  • 3 auditor resignation(s) filed - latest: DELOITTE HASKINS & SELLS LLP on 2023-05-30.
  • Delayed payments to MSME suppliers disclosed (2 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 40/100
NameDIN / PANDesignationAppointedTenureDIN status
PERUMAL MANOHARAN 01234567 Director 01/04/2018 6 yrs Approved
ADITYA DESIRAJU 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • ADITYA DESIRAJU has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • 1 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Tenshi Kaizen Private Limited
Subsidiaries
-
Group entities
-
Capital events
7 allotment(s) · 3 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Tenshi Kaizen Private Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 50 · Distress 35
Growth signals & trust indicators
Latest year revenue grew 38%.
Operating for 20+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Outside liabilities up 1.42 in a year.
Negative net worth.
Statutory filings appear overdue.
Compliance score is weak (43/100).
3 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 7.70 Lakh.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence41/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 4 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment37/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view38/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 15 events
30 Jul 2025
Last AGM held
Annual general meeting
29 Sep 2023
Director ceased
PERUMAL MANOHARAN
31 Mar 2023
Latest balance sheet
Filed with ROC
02 Mar 2023
Director appointed
PERUMAL MANOHARAN (Director)
Director appointed
ADITYA DESIRAJU (Director)
Director ceased
CHANDRAPPA SEETHARAMAIAH
Director ceased
ADITYA ARUN KUMAR
22 Jan 2021
Director ceased
PUDHUCODE RADHAKRISHNAN KANNAN
31 Mar 2020
Share transfer (FY 2020)
450.00000000 shares to Archana Bhat
19 Jun 2019
Securities allotted
32845 Equity Shares - 4.38 cr raised
12 Jun 2019
Director ceased
IRFAN ULLA SHARIEFF
Director ceased
ADITYA DESIRAJU
03 Jun 2019
Director ceased
SURESH SHARMA
18 May 2018
Securities allotted
4872 Equity Shares - 64.94 Lakh raised
09 Apr 2018
Securities allotted
4478 Equity Shares - 59.69 Lakh raised
10

Key Observations

Auto-generated from the data above
Revenue declined 2.1x over the last 4 financial year(s).
2 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 7 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Rishabh Drugs Private Limited U33125DL1991PTC045326 New Delhi, Delhi, India
Archean U14220TN2014PTC096884 Egmore Nungambakka, Tamil Nadu, India
Umasha Processing Private Limited U36997BR2019PTC040617 Muzaffarpur, Bihar, India
Linear Pharma Private Limited U74899DL1988PTC031611 East Delhi, Delhi, India
Aktriana Private Limited U74999WB2017PTC223268 Bally Jagachha, West Bengal, India
Kothari Thermoplast Private Limited U24222DL2004PTC127975 New Delhi, Delhi, India
G S Solvent Private Limited U51109PN1999PTC208707 Pune, Maharashtra, India
Ganpati Aloe Vera Herbs Private Limited U24247DL2007PTC162087 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Triphase Pharmaceuticals Private Limited before audits and certifications: compliance score 43/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Triphase Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 50/100, margin trends, ownership structure and peer set for Triphase Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 44/100, distress signals and MSME payment-delay disclosures - know whether Triphase Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Triphase Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Triphase Pharmaceuticals Private Limited an active company?

Triphase Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 43/100 (Caution Indicated).

Is Triphase Pharmaceuticals Private Limited financially healthy?

Triphase Pharmaceuticals Private Limited has a Financial Health Score of 20/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Triphase Pharmaceuticals Private Limited?

Its overall Trust Score is 44/100 (Caution Indicated). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Triphase Pharmaceuticals Private Limited?

The ultimate holding entity is Tenshi Kaizen Private Limited. 2 active director(s) are on record.

Does Triphase Pharmaceuticals Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Triphase Pharmaceuticals Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 43/100 (Caution Indicated).

Is it risky to lend to Triphase Pharmaceuticals Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.